Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of TO-194SL Sublingual Therapy for Japanese Cedar Pollinosis
jRCT2080221222Phase 3
- Sponsor
- Torii Pharmaceutical
- Start
- Sep 2010
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Japanese cedar pollinosis and seasonal allergic rhinitis (SAR) comparing TO-194SL sublingual with Placebo sublingual (2 arms).
02
Drugs
japanese cedar pollen extract
03
Conditions
Japanese cedar pollinosisseasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on jRCT2080221222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221222.